IDEXX Laboratories Posts Strong Q1 Growth and Raises Revenue Outlook Amid New Cancer Diagnostic Launch

IDEXX Laboratories, a global veterinary diagnostics leader, has kicked off 2025 with a solid start—reporting stronger-than-expected first-quarter earnings, boosting revenue guidance, and showcasing a groundbreaking innovation in canine cancer diagnostics.

Key Highlights:

  • Q1 Revenue: $998 million, up 4% reported and 5% organically

  • EPS: $2.96, up 5% reported and 7% on a comparable basis

  • CAG Diagnostics Recurring Revenue: Up 3% reported, 4.5% organic

  • Updated 2025 Revenue Guidance: $4.095B to $4.210B (up $40 million from prior estimates)

  • 2025 EPS Forecast: $11.93 to $12.43 (up $0.19 from previous guidance)

Innovation Spotlight: IDEXX Cancer Dx™

A major buzz from the quarter was the launch of IDEXX Cancer Dx™, a novel diagnostic panel targeting early detection of canine lymphoma. Described by CEO Jay Mazelsky as a direct response to veterinarians’ calls for earlier, actionable cancer diagnostics, this new tool aims to be both fast and affordable, integrating seamlessly into common wellness and sick-patient panels.

What’s Driving the Numbers?

  • Continued VetLab® consumables strength, up 9% reported and 10% organic

  • Over 300 inVue Dx™ analyzers installed globally

  • 9% revenue growth in veterinary software, services, and imaging

  • CAG Diagnostics recurring revenue growth was particularly robust internationally, with 8.5% organic growth outside the U.S.

Areas to Watch

  • Reference Lab Growth: Flat, with only 1% organic growth, indicating a potential plateau in this segment

  • Rapid Assays: Declined 3% reported and 2% organic, largely due to a shift in testing volume toward newly launched products like the Catalyst® Pancreatic Lipase Test

Why the Upgraded Forecast?

Currency tailwinds, favorable litigation adjustments, and overall strong product execution led IDEXX to raise its full-year guidance. The company now expects:

  • 5%–8% reported revenue growth (up from 4%–7%)

  • 12%–17% EPS growth (up from 10%–15%)

  • Maintained organic growth projections at 6%–9%

With capital expenditures holding steady at $160 million and a projected 31.1%–31.6% operating margin, IDEXX is showing confidence in its innovation-led growth strategy. Even with global trade uncertainties and modest declines in specific product lines, the company is leaning into R&D and cloud software investments.

As the demand for advanced diagnostics grows alongside pet ownership and veterinary care complexity, IDEXX seems positioned to not only meet expectations—but surpass them.

Previous
Previous

The Future of Veterinary Neurology Is Now—and It Has Swagger

Next
Next

“Shelter Me: The Cancer Pioneers” Trailer Debuts, Showcasing How Dogs Are Helping Unlock the Future of Cancer Treatment